A carregar...
Olaparib Combined with an ATR or Chk1 Inhibitor as a Treatment Strategy for Acquired Olaparib-Resistant BRCA1 Mutant Ovarian Cells
Objective: Despite the promise of PARP inhibitors (PARPi) for treating BRCA1/2 mutated ovarian cancer (OC), drug resistance invariably develops. We hypothesized rationale drug combinations, targeting key molecules in DNA repair pathways and the cell cycle may be synergistic and overcome acquired PAR...
Na minha lista:
| Publicado no: | Diagnostics (Basel) |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MDPI
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7168282/ https://ncbi.nlm.nih.gov/pubmed/32098452 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/diagnostics10020121 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|